2025年7月31日，宁德时代(300750.SZ)发布2025年中报。 公司最新总资产周转率为0.22次，较去年同期总资产周转率减少0.02次，同比较去年同期下降7.09%。 最新存货周转率为2.03次，较去年同期存货周转率减少0.59次，同比较去年同期下降22.53%。 公司营业总收入为1788.86亿元。归母净利润为304.85亿元。经营活动现金净流入为586.87亿元。 公司股东户数为22.64万户，前十大股东持股数量为29.25亿股，占总股本比例为64.16%，前十大股东持 股情况如下： 公司最新资产负债率为62.59%。 公司最新毛利率为25.02%，较去年同期毛利率减少1.51个百分点。最新ROE为10.34%，较去年同期ROE 减少1.32个百分点。 公司摊薄每股收益为6.92元。 | 序号 | 股东名称 | 持股比例 | | --- | --- | --- | | J | 厦门瑞庭投资有限公司 | 22.47% | | 2 | 香港中央结算有限公司 | 13.31% | | 3 | 黄世霖 | 10.22% | | 4 | 宁波联合创新新能源投资管理合伙企业(有限合伙) | 6.23% | ...

公司最新毛利率为38.42%，较去年同期毛利率增加2.90个百分点，实现3年连续上涨。最新ROE为 5.52%。 2025年7月31日，厦门空港(600897.SH)发布2025年中报。 公司营业总收入为9.91亿元，较去年同报告期营业总收入增加6569.56万元，实现3年连续上涨，同比较 去年同期上涨7.10%。归母净利润为2.53亿元，较去年同报告期归母净利润增加275.27万元，实现3年连 续上涨，同比较去年同期上涨1.10%。经营活动现金净流入为3.17亿元。 公司最新资产负债率为19.03%，较去年同期资产负债率减少0.13个百分点。 公司摊薄每股收益为0.61元，较去年同报告期摊薄每股收益增加0.01元，实现3年连续上涨，同比较去年 同期上涨1.10%。 公司最新总资产周转率为0.17次，较去年同期总资产周转率持平，实现3年连续上涨，同比较去年同期 上涨0.60%。最新存货周转率为1366.45次，较去年同期存货周转率增加314.46次，实现3年连续上涨， 同比较去年同期上涨29.89%。 公司股东户数为1.72万户，前十大股东持股数量为3.06亿股，占总股本比例为73.39%。 ...

公司摊薄每股收益为0.41元。 公司最新总资产周转率为0.36次，较去年同期总资产周转率减少0.12次，同比较去年同期下降24.81%。最新存货周转率为1.32次，较去年同期存货周转率减 少0.34次，同比较去年同期下降20.29%。 公司股东户数为3.84万户，前十大股东持股数量为1.82亿股，占总股本比例为72.46%，前十大股东持股情况如下： | 序号 | 股东名称 | 持股 | | --- | --- | --- | | 1 | 袁微微 | 39.6 | | 2 | 郭旭辉 | 30.2 | | 3 | 香港中央结算有限公司 | 0.49 | | ব | 东台智展企业管理合伙企业(有限合伙) | 0.32 | | 5 | 中国银行股份有限公司-易方达供给改革灵活配置混合型证券投资基金 | 0.32 | | 6 | 中国农业银行股份有限公司 宝盈策略增长混合型证券投资基金 | 0.30 | | 7 | 招商银行股份有限公司-南方中证1000交易型开放式指数证券投资基金 | 0.28 | | 8 | 马新成 | 0.27 | | g | 中国农业银行股份有限公司-宝盈科技30灵活配置混合型证券投资基金 | ...

Core Insights - The company reported a total revenue of 404 million yuan for the first half of 2025, an increase of 71.08 million yuan compared to the same period last year, marking a year-on-year growth of 21.34% [1] - The net profit attributable to shareholders reached 135 million yuan, up by 21.96 million yuan from the previous year, reflecting a year-on-year increase of 19.50% [1] - The company achieved a net cash inflow from operating activities of 55.27 million yuan [1] Financial Metrics - The latest debt-to-asset ratio stands at 25.02% [2] - The gross profit margin is reported at 57.34% [3] - Return on equity (ROE) is at 5.67%, an increase of 0.38 percentage points compared to the same period last year [3] - The diluted earnings per share (EPS) is 0.35 yuan, an increase of 0.06 yuan year-on-year, representing a growth of 18.95% [3] - The total asset turnover ratio is 0.13 times, remaining stable compared to the previous year, with a year-on-year increase of 2.26% [3] - The inventory turnover ratio is 0.34 times, an increase of 0.10 times from the previous year, reflecting a year-on-year growth of 41.51% [3] Shareholder Information - The number of shareholders is 41,800, with the top ten shareholders holding a total of 80.91 million shares, accounting for 20.77% of the total share capital [3] - The largest shareholder is Li Haiying, holding 7.95% of the shares [3]

Core Insights - Guobang Pharmaceutical (605507.SH) reported its 2025 mid-year financial results, highlighting a total revenue of 3.026 billion yuan and a net profit attributable to shareholders of 456 million yuan [2]. Financial Performance - The company's total revenue reached 3.026 billion yuan, with a net profit of 456 million yuan [2]. - Operating cash flow showed a net inflow of 103 million yuan [2]. - The latest gross profit margin was recorded at 26.85%, while the return on equity (ROE) stood at 5.65% [5]. - The diluted earnings per share were reported at 0.82 yuan [6]. Balance Sheet Metrics - The current asset-liability ratio is 25.41%, which reflects an increase of 0.52 percentage points compared to the same period last year [4]. - The total asset turnover ratio remained stable year-on-year, although it decreased by 0.88% compared to the previous year [6]. - The inventory turnover ratio was 1.55 times, showing a decrease of 0.02 times year-on-year, which is a decline of 0.97% compared to the same period last year [6]. Shareholder Structure - The number of shareholders is approximately 25,000, with the top ten shareholders holding a total of 357 million shares, accounting for 63.85% of the total share capital [6]. - The largest shareholder is Xinchang Ander Trading Co., Ltd., holding 23.08% of the shares [6].

Core Insights - Enhua Pharmaceutical (002262.SZ) reported a total revenue of 3.01 billion yuan for the first half of 2025, with a net profit attributable to shareholders of 700 million yuan [1] Financial Performance - The company's operating cash flow decreased by 127 million yuan compared to the same period last year, representing a year-on-year decline of 20.43% [1] - The latest asset-liability ratio stands at 13.01%, an increase of 0.87 percentage points from the same period last year [2] - The gross profit margin is reported at 75.24%, while the return on equity (ROE) is 9.13%, down by 0.20 percentage points year-on-year [3] - The diluted earnings per share are 0.69 yuan [4] - The total asset turnover ratio is 0.35 times, a decrease of 0.02 times compared to the same period last year, reflecting a year-on-year decline of 5.36% [4] - The inventory turnover ratio is 1.06 times, down by 0.22 times year-on-year, indicating a decline of 17.37% [4] Shareholder Structure - The number of shareholders is reported at 43,600, with the top ten shareholders holding a total of 550 million shares, accounting for 54.16% of the total share capital [4] - The largest shareholder, Xuzhou Enhua Investment Co., Ltd., holds 31.50% of the shares [4]

Core Insights - The company reported a total operating revenue of 9.335 billion yuan and a net profit attributable to shareholders of 296 million yuan for the first half of 2025 [1] - The company experienced a significant decrease in cash flow from operating activities, with a net outflow of 1.183 billion yuan, a reduction of 306 million yuan compared to the same period last year [1] Financial Performance - The latest asset-liability ratio stands at 59.63%, which is an increase of 3.55 percentage points from the previous quarter and an increase of 7.41 percentage points year-on-year [3] - The company's gross profit margin is 10.32%, reflecting a decrease of 0.67 percentage points compared to the same period last year [4] - The return on equity (ROE) is reported at 7.22% [4] - The diluted earnings per share (EPS) is 0.40 yuan [5] - The total asset turnover ratio is 0.86 times, a decline of 0.03 times or 3.40% year-on-year [5] - The inventory turnover ratio is 5.15 times [5] Shareholder Structure - The number of shareholders is 43,800, with the top ten shareholders holding a total of 313 million shares, accounting for 42.67% of the total share capital [5] - The largest shareholder is Shenzhen Nengxiang Investment Development Co., Ltd., holding 15.69% of the shares [5]

墨西哥国家石油公司（PEMEX）第二季度净利润为595.2亿墨西哥比索，而2024年第二季度亏损为2733 亿墨西哥比索。 美元/墨西哥比索 ...

Investment Rating - Industry Rating: Recommended [5] Core Insights - In Q2 2025, Newmont's attributable gold production was 1.48 million ounces (approximately 46.03 tons), a decrease of 3.9% quarter-over-quarter and 8.1% year-over-year, primarily due to the completion of non-core asset sales [2] - The average realized gold price in Q2 2025 was $3,320 per ounce, reflecting a quarter-over-quarter increase of 12.8% and a year-over-year increase of 41.5% [2] - The adjusted net income for Q2 2025 was $1.594 billion, representing a quarter-over-quarter growth of 13.5% and a year-over-year growth of 91.1% [6] Production and Operational Performance - Q2 2025 gold unit sales cost (CAS) excluding by-product revenue was $1,215 per ounce, a decrease of 1.0% quarter-over-quarter but an increase of 5.5% year-over-year [3] - The all-in sustaining cost (AISC) excluding by-product revenue was $1,593 per ounce, down 3.5% quarter-over-quarter but up 2.0% year-over-year [3] - The company expects approximately 50% of its gold production for 2025 to come from the second half of the year, with anticipated increases from Nevada and Yanacocha mines [8] Financial Performance - Newmont's sales revenue for Q2 2025 was $5.317 billion, a quarter-over-quarter increase of 6.1% and a year-over-year increase of 20.8% [4] - The adjusted EBITDA for Q2 2025 was $2.997 billion, reflecting a quarter-over-quarter increase of 14.0% and a year-over-year increase of 52.4% [6] - Free cash flow for Q2 2025 was $1.710 billion, a quarter-over-quarter increase of 41.9% and a year-over-year increase of 187.9% [7] Asset Divestiture and Guidance - Newmont has completed the sale of all non-core businesses and expects total proceeds from announced transactions to reach up to $4.3 billion, with $2.5 billion in net cash received so far in 2025 [12] - The company maintains its production guidance for 2025, with total attributable gold production expected to be 5.9 million ounces [15]

Company Overview - Yueyang Xingchang's closing price on July 1 was 15.44 yuan, down 1.34%, with a rolling PE ratio of 103.53 times and a total market value of 5.708 billion yuan [1] - The company operates in the petrochemical sector, focusing on the development, production, and sales of chemical new materials, energy conservation and environmental protection, and energy chemical products [1] - Main products include methyl tert-butyl ether, liquefied petroleum gas, propylene, industrial isooctane, ortho-cresol, calcined petroleum coke, and special polypropylene [1] Financial Performance - For Q1 2025, the company reported operating revenue of 1.063 billion yuan, a year-on-year increase of 27.85% [1] - Net profit for the same period was 13.6081 million yuan, reflecting a year-on-year decrease of 37.00% [1] - The sales gross margin stood at 18.85% [1] Shareholder Information - As of March 31, 2025, the number of shareholders was 22,331, an increase of 408 from the previous count [1] - The average market value of shares held per shareholder was 352,800 yuan, with an average holding of 27,600 shares [1] Industry Comparison - The average PE ratio for the petrochemical industry is 12.81 times, with a median of 29.80 times, positioning Yueyang Xingchang at 19th place within the industry [2] - The company's PE ratio is significantly higher than the industry average, indicating potential overvaluation compared to peers [2]